Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a Phase III clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.
The results, published in The Lancet, may change the standard of care for many patients with prostate-specific membrane antigen (PSMA)-positive metastatic prostate cancer.
The standard backbone of therapy had been an androgen receptor pathway inhibitor (ARPI) paired with androgen deprivation therapy (ADT). But the trial showed that adding a targeted radionuclide therapy drug called 177Lu-PSMA-617, or lutetium PSMA 617 vipivotide tetraxetan, to backbone therapy in patients with PSMA-positive cancer reduces the risk of disease progression, as determined by scans, or death by 28% when given soon after diagnosis of metastatic cancer.
Results of the study and ongoing analyses led the U.S. Food and Drug Administration to approve early use of the drug for PSMA-positive metastatic prostate cancer in late July.
A broader option at diagnosis
